In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and nivolumab doubled the progression-free survival benefit compared to nivolumab alone, with a manageable safety profile, ...
Jan 5, 2022
0
56
More people with advanced melanoma survive for two years or more when they receive a combination of two immunotherapy drugs given before a combination of two targeted therapies, if needed, compared to people who start treatment ...
Nov 15, 2021
0
10
Results of an international clinical trial co-led by researchers at Winship Cancer Institute at Emory University show potential for a novel drug to benefit patients with multiple myeloma whose disease either recurred or was ...
Aug 3, 2022
0
1509
Glioblastoma is the most aggressive type of primary brain cancer, one with a prognosis of 11-15 months with standard treatment. Results from a phase 1b clinical trial of a new experimental glioblastoma vaccine developed by ...
Mar 31, 2019
0
16
A combination of two drugs keeps patients with chronic lymphocytic leukemia disease-free and alive longer than the current standard of care, according to a phase-3 clinical trial of more than 500 participants conducted at ...
Jul 31, 2019
0
108
For patients with AIDS-related lymphoma (ARL), hypoalbuminemia predicts inferior outcome, according to a study published online June 18 in Infectious Agents and Cancer.
Jun 24, 2022
0
66
A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly ...
Jun 4, 2023
0
54
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer. This is the finding of the long-term analyses of an international phase ...
Sep 29, 2020
0
9
A four-drug chemotherapy regimen provided longer overall survival than a two-drug combination in a Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma. The study is believed to be the first metastatic pancreatic ...
Jan 20, 2023
0
5
For patients with previously untreated metastatic or unresectable melanoma, the combination of relatlimab + nivolumab continues to demonstrate a progression-free survival (PFS) benefit over nivolumab alone, according to updated ...
Mar 21, 2022
0
13
